

Hanxiao You

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/956318/publications.pdf>

Version: 2024-02-01

15
papers

210
citations

1478458

6
h-index

1125717

13
g-index

18
all docs

18
docs citations

18
times ranked

234
citing authors

#	ARTICLE	IF	CITATIONS
1	JAK Inhibitors: Prospects in Connective Tissue Diseases. <i>Clinical Reviews in Allergy and Immunology</i> , 2020, 59, 334-351.	6.5	83
2	Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1441-1443.	0.9	43
3	Tofacitinib as a possible treatment for skin thickening in diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2021, 60, 2472-2477.	1.9	20
4	Predicting the Risk of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: A Chinese Systemic Lupus Erythematosus Treatment and Research Group Cohort Study. <i>Arthritis and Rheumatology</i> , 2021, 73, 1847-1855.	5.6	18
5	Evaluation of the Diagnostic Value of Non-criteria Antibodies for Antiphospholipid Syndrome Patients in a Chinese Cohort. <i>Frontiers in Immunology</i> , 2021, 12, 741369.	4.8	10
6	Comparison of Different Test Systems for the Detection of Antiphospholipid Antibodies in a Chinese Cohort. <i>Frontiers in Immunology</i> , 2021, 12, 648881.	4.8	9
7	Risk of osteonecrosis in systemic lupus erythematosus: An 11-year Chinese single-center cohort study. <i>Lupus</i> , 2021, 30, 1459-1468.	1.6	8
8	Clinical Characteristics of Systemic Lupus Erythematosus with Cirrhosis. <i>Journal of Immunology Research</i> , 2020, 2020, 1-7.	2.2	5
9	The Effects of Genetic Polymorphism on Treatment Response of Recombinant Human Growth Hormone. <i>Current Drug Metabolism</i> , 2018, 19, 1159-1167.	1.2	4
10	Characteristics and risk factors of pulmonary embolism in patients with systemic lupus erythematosus: a single-center cohort study. , 2020, , .		3
11	Prognostic factors of systemic lupus erythematosus patients with pulmonary embolism: An 11-year cohort study. <i>Lupus</i> , 2022, 31, 885-890.	1.6	3
12	Characteristics and risk factors of pulmonary embolism in patients with systemic lupus erythematosus: a case control study. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 940-948.	0.8	2
13	Early Initiation of Anticoagulation Improves the Long-Term Prognosis in Patients With Antiphospholipid Syndrome Associated Portal Vein Thrombosis. <i>Frontiers in Medicine</i> , 2021, 8, 630660.	2.6	1
14	Chinese SLE Treatment and Research Group Registry (CSTAR) XIII: prevalence and risk factors for chronic scarring alopecia in patients with systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2021, 23, 20.	3.5	1
15	Early efficient anticoagulation improves the long-term prognosis in patients with antiphospholipid syndrome associated portal vein thrombosis. , 2020, , .		0